A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
NCT ID: NCT01923740
Last Updated: 2019-12-04
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
480 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-07-31
Study Completion Date
2019-03-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Absorb IV Randomized Controlled Trial
NCT02173379
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Disease
+1 more
COMPLETED
NA
ABSORB II Randomized Controlled Trial
NCT01425281
Coronary Artery Disease
COMPLETED
NA
ABSORB Clinical Investigation, Cohort B
NCT00856856
Coronary Disease
Coronary Artery Disease
Coronary Restenosis
COMPLETED
NA
ABSORB III Randomized Controlled Trial (RCT)
NCT01751906
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Disease
+1 more
COMPLETED
NA
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
NCT02831205
Percutaneous Transluminal Coronary Angioplasty
TERMINATED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Coronary Artery Disease
Coronary Artery Stenosis
Coronary Disease
Coronary Stenosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Absorb BVS System
Absorb BVS System: Subjects receiving Absorb BVS System
Group Type
EXPERIMENTAL
Absorb BVS System
Intervention Type
DEVICE
Subjects receiving Absorb BVS System
XIENCE V EECSS
XIENCE V EECSS: Subjects receiving XIENCE V
Group Type
ACTIVE_COMPARATOR
XIENCE V EECSS
Intervention Type
DEVICE
Subjects receiving XIENCE V
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XIENCE V EECSS
Subjects receiving XIENCE V
Intervention Type
DEVICE
Absorb BVS System
Subjects receiving Absorb BVS System
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject must be at least 18 years of age at the time of signing the informed consent form.
2. Subject or a legally authorized representative must provide written Informed Consent prior to any study related procedure.
3. Subject must have evidence of myocardial ischemia (e.g., stable angina, unstable angina, post-infarct angina or silent ischemia) suitable for elective percutaneous coronary intervention (PCI). Subjects with stable angina or silent ischemia and \< 70% diameter stenosis must have objective sign of ischemia as determined by one of the following, echocardiogram, nuclear scan, ambulatory ECG or stress ECG. In the absence of noninvasive ischemia, fractional flow reserve (FFR) must be done and indicative of ischemia.
4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
5. Female subject of childbearing potential does not plan pregnancy for up to 1 year following the index procedure. For a female subject of childbearing potential, a pregnancy test must be performed with negative results known within 14 days (≤14 days) prior to the index procedure per site standard test.
6. Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 1 year following the index procedure.
7. Subject agrees to not participate in any other investigational clinical studies for a period of 1 year following the index procedure.
Assessment of angiographic eligibility is per visual assessment by an investigator both for qualitative and quantitative variables. On-line QCA is recommended to be used for appropriately sizing of the vessel. If on-line QCA cannot be used, visual estimation is required.
1. One or two de novo target lesions:
1. If there is one target lesion, a second non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful, uncomplicated result prior to randomization of the target lesion.
2. If two target lesions are present, they must be present in different epicardial vessels and both satisfy the angiographic eligibility criteria.
3. The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a diagonal branch.
2. Target lesion must be located in a native coronary artery with a visually estimated or quantitatively assessed %DS of ≥ 50% and \< 100% with a thrombolysis in myocardial infarction (TIMI) flow of ≥ 1 and one of the following: stenosis ≥ 70%, an abnormal functional test (e.g., fractional flow reserve, stress test), unstable angina or post-infarct angina.
3. Target lesion must have a Dmax (by on-line QCA) or reference vessel diameter (RVD) (by visual estimation) ≥ 2.50 mm and ≤ 3.75 mm (on-line QCA assessment is recommended).
4. Target lesion must have a lesion length ≤ 24 mm based on either visual estimation or on-line QCA.
2. Subject or a legally authorized representative must provide written Informed Consent prior to any study related procedure.
3. Subject must have evidence of myocardial ischemia (e.g., stable angina, unstable angina, post-infarct angina or silent ischemia) suitable for elective percutaneous coronary intervention (PCI). Subjects with stable angina or silent ischemia and \< 70% diameter stenosis must have objective sign of ischemia as determined by one of the following, echocardiogram, nuclear scan, ambulatory ECG or stress ECG. In the absence of noninvasive ischemia, fractional flow reserve (FFR) must be done and indicative of ischemia.
4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.
5. Female subject of childbearing potential does not plan pregnancy for up to 1 year following the index procedure. For a female subject of childbearing potential, a pregnancy test must be performed with negative results known within 14 days (≤14 days) prior to the index procedure per site standard test.
6. Female subject is not breast-feeding at the time of the screening visit and will not be breast-feeding for up to 1 year following the index procedure.
7. Subject agrees to not participate in any other investigational clinical studies for a period of 1 year following the index procedure.
Assessment of angiographic eligibility is per visual assessment by an investigator both for qualitative and quantitative variables. On-line QCA is recommended to be used for appropriately sizing of the vessel. If on-line QCA cannot be used, visual estimation is required.
1. One or two de novo target lesions:
1. If there is one target lesion, a second non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful, uncomplicated result prior to randomization of the target lesion.
2. If two target lesions are present, they must be present in different epicardial vessels and both satisfy the angiographic eligibility criteria.
3. The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a diagonal branch.
2. Target lesion must be located in a native coronary artery with a visually estimated or quantitatively assessed %DS of ≥ 50% and \< 100% with a thrombolysis in myocardial infarction (TIMI) flow of ≥ 1 and one of the following: stenosis ≥ 70%, an abnormal functional test (e.g., fractional flow reserve, stress test), unstable angina or post-infarct angina.
3. Target lesion must have a Dmax (by on-line QCA) or reference vessel diameter (RVD) (by visual estimation) ≥ 2.50 mm and ≤ 3.75 mm (on-line QCA assessment is recommended).
4. Target lesion must have a lesion length ≤ 24 mm based on either visual estimation or on-line QCA.
Exclusion Criteria
1. Any surgery requiring general anesthesia or discontinuation of aspirin and/or P2Y12 inhibitor is planned within 12 months after the index procedure.
2. Subject has a known hypersensitivity or contraindication to device material (cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers) and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid). Subject has a known contrast sensitivity that cannot be adequately pre-medicated.
3. Subject has a known allergic reaction, hypersensitivity or contraindication to:
1. Aspirin; or
2. All P2Y12 inhibitors (including clopidogrel and ticlopidine, and prasugrel and ticagrelor when they become available); or
3. Heparin and bivalirudin.
4. Subject had an acute myocardial infarction (AMI) within 7 days of the index procedure and both creatine kinase (CK) and creatine kinase myocardial-band isoenzyme (CK-MB) have not returned to within normal limits at the time of index procedure.
5. Subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.
6. Subject has a cardiac arrhythmia as identified at the time of screening which at least one of the following criteria is met:
1. Subject requires coumadin or any other agent for chronic oral anticoagulation.
2. Subject likely to become hemodynamically unstable due to their arrhythmia.
3. Subject has poor survival prognosis due to their arrhythmia.
7. Subject has a known left ventricular ejection fraction (LVEF) \< 30% assessed by any quantitative method. LVEF may be obtained within 6 months prior to the procedure for subjects with stable coronary artery disease (CAD). For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed during the index hospitalization (which may include during the index procedure by contrast left ventriculography) but prior to randomization in order to confirm the subject's eligibility.
8. Subject has received CABG at any time in the past.
9. Subject has undergone prior PCI within the target vessel during the last 12 months or undergone prior PCI within the non-target vessel within 30 days before the index procedure.
10. Subject requires future staged PCI either in target or non-target vessels.
11. Subject has received any solid organ transplants or is on a waiting list for any solid organ transplants.
12. At the time of screening, the subject has a malignancy that is not in remission.
13. Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
14. Subject has previously received or is scheduled to receive radiotherapy to coronary artery (vascular brachytherapy), or chest/mediastinum.
15. Subject is receiving or will receive chronic anticoagulation therapy (e.g., coumadin or any other anticoagulation agents).
16. Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3.
17. Subject has a known or documented hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
18. Subject has known renal insufficiency as defined as an estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 or dialysis at the time of screening.
19. Subject is high risk of bleeding; has a history of bleeding diathesis or coagulopathy; has had a significant gastro-intestinal or significant urinary bleed within the past six months; will refuse blood transfusions.
20. Subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months or any prior intracranial bleed, any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc.).
21. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion. Note: femoral arterial disease does not exclude the subject if radial or brachial access can be used.
22. Subject has life expectancy \< 2 years for any non-cardiac cause or cardiac cause.
23. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.
24. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint or protocol-required medications or invasive procedures.
1. Target lesion is located in left main.
2. Aorto-ostial RCA target lesion (within 3 mm of the ostium).
3. Target lesion located within 3 mm of the origin of the LAD or LCX.
4. Lesion involving a bifurcation with a:
1. Side branch ≥ 2 mm in diameter, or
2. Side branch with diameter stenosis ≥ 50%, or
3. Side branch requiring protection guide wire, or
4. Side branch requiring pre-dilatation
5. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or XIENCE V, including:
1. Extreme angulation (≥ 90°) proximal to or within the target lesion
2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion
3. Moderate or heavy calcification proximal to or within the target lesion
6. Target lesion or target vessel involves a myocardial bridge.
7. Target vessel contains thrombus as indicated in the angiographic images.
8. Target vessel has been previously treated with a stent at any time prior to the index procedure such that the Absorb BVS or XIENCE V would need to cross the stent to reach the target lesion.
9. Target vessel has been previously treated with a stent and the target lesion is within 5 mm proximal to a previously treated lesion.
10. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon expansion with the following outcomes:
1. Residual %DS is \< 40% (per visual estimation), ≤ 20% is strongly recommended.
2. TIMI Grade-3 flow (per visual estimation).
3. No angiographic complications (e.g. distal embolization, side branch closure).
4. No dissections National Heart, Lung, and Blood Institute (NHLBI) grade D-F.
5. No chest pain lasting \> 5 minutes.
6. No ST depression or elevation lasting \> 5 minutes.
2. Subject has a known hypersensitivity or contraindication to device material (cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers) and its degradants (everolimus, poly (L-lactide), poly (DL-lactide), lactide, lactic acid). Subject has a known contrast sensitivity that cannot be adequately pre-medicated.
3. Subject has a known allergic reaction, hypersensitivity or contraindication to:
1. Aspirin; or
2. All P2Y12 inhibitors (including clopidogrel and ticlopidine, and prasugrel and ticagrelor when they become available); or
3. Heparin and bivalirudin.
4. Subject had an acute myocardial infarction (AMI) within 7 days of the index procedure and both creatine kinase (CK) and creatine kinase myocardial-band isoenzyme (CK-MB) have not returned to within normal limits at the time of index procedure.
5. Subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.
6. Subject has a cardiac arrhythmia as identified at the time of screening which at least one of the following criteria is met:
1. Subject requires coumadin or any other agent for chronic oral anticoagulation.
2. Subject likely to become hemodynamically unstable due to their arrhythmia.
3. Subject has poor survival prognosis due to their arrhythmia.
7. Subject has a known left ventricular ejection fraction (LVEF) \< 30% assessed by any quantitative method. LVEF may be obtained within 6 months prior to the procedure for subjects with stable coronary artery disease (CAD). For subjects presenting with acute coronary syndrome (ACS), LVEF must be assessed during the index hospitalization (which may include during the index procedure by contrast left ventriculography) but prior to randomization in order to confirm the subject's eligibility.
8. Subject has received CABG at any time in the past.
9. Subject has undergone prior PCI within the target vessel during the last 12 months or undergone prior PCI within the non-target vessel within 30 days before the index procedure.
10. Subject requires future staged PCI either in target or non-target vessels.
11. Subject has received any solid organ transplants or is on a waiting list for any solid organ transplants.
12. At the time of screening, the subject has a malignancy that is not in remission.
13. Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.). Note: corticosteroids are not included as immunosuppressant therapy.
14. Subject has previously received or is scheduled to receive radiotherapy to coronary artery (vascular brachytherapy), or chest/mediastinum.
15. Subject is receiving or will receive chronic anticoagulation therapy (e.g., coumadin or any other anticoagulation agents).
16. Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3.
17. Subject has a known or documented hepatic disorder as defined as cirrhosis or Child-Pugh ≥ Class B.
18. Subject has known renal insufficiency as defined as an estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 or dialysis at the time of screening.
19. Subject is high risk of bleeding; has a history of bleeding diathesis or coagulopathy; has had a significant gastro-intestinal or significant urinary bleed within the past six months; will refuse blood transfusions.
20. Subject has had a cerebrovascular accident or transient ischemic neurological attack (TIA) within the past six months or any prior intracranial bleed, any permanent neurologic defect, or any known intracranial pathology (e.g., aneurysm, arteriovenous malformation, etc.).
21. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion. Note: femoral arterial disease does not exclude the subject if radial or brachial access can be used.
22. Subject has life expectancy \< 2 years for any non-cardiac cause or cardiac cause.
23. Subject is in the opinion of the Investigator or designee, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason.
24. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint or protocol-required medications or invasive procedures.
1. Target lesion is located in left main.
2. Aorto-ostial RCA target lesion (within 3 mm of the ostium).
3. Target lesion located within 3 mm of the origin of the LAD or LCX.
4. Lesion involving a bifurcation with a:
1. Side branch ≥ 2 mm in diameter, or
2. Side branch with diameter stenosis ≥ 50%, or
3. Side branch requiring protection guide wire, or
4. Side branch requiring pre-dilatation
5. Anatomy proximal to or within the lesion that may impair delivery of the Absorb BVS or XIENCE V, including:
1. Extreme angulation (≥ 90°) proximal to or within the target lesion
2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion
3. Moderate or heavy calcification proximal to or within the target lesion
6. Target lesion or target vessel involves a myocardial bridge.
7. Target vessel contains thrombus as indicated in the angiographic images.
8. Target vessel has been previously treated with a stent at any time prior to the index procedure such that the Absorb BVS or XIENCE V would need to cross the stent to reach the target lesion.
9. Target vessel has been previously treated with a stent and the target lesion is within 5 mm proximal to a previously treated lesion.
10. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon expansion with the following outcomes:
1. Residual %DS is \< 40% (per visual estimation), ≤ 20% is strongly recommended.
2. TIMI Grade-3 flow (per visual estimation).
3. No angiographic complications (e.g. distal embolization, side branch closure).
4. No dissections National Heart, Lung, and Blood Institute (NHLBI) grade D-F.
5. No chest pain lasting \> 5 minutes.
6. No ST depression or elevation lasting \> 5 minutes.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Medical Devices
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gao Runlin, MD, FACC
Role: PRINCIPAL_INVESTIGATOR
Fu Wai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abbott Vascular
Santa Clara, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, Chevalier B, Simonton C, Dressler O, Crowley A, Ali ZA, Serruys PW. Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study. JAMA Cardiol. 2019 Dec 1;4(12):1261-1269. doi: 10.1001/jamacardio.2019.4101.
Reference Type
DERIVED
Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, Chevalier B, Vu MT, Zhang Z, Simonton CA, Serruys PW, Stone GW. Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials. Circulation. 2018 Jan 30;137(5):464-479. doi: 10.1161/CIRCULATIONAHA.117.031843. Epub 2017 Oct 31.
Reference Type
DERIVED
Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016 Mar 26;387(10025):1277-89. doi: 10.1016/S0140-6736(15)01039-9. Epub 2016 Jan 27.
Reference Type
DERIVED
Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015 Dec 1;66(21):2298-2309. doi: 10.1016/j.jacc.2015.09.054. Epub 2015 Oct 12.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-397
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
NCT02474485
SUSPENDED
NA
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
NCT01844284
COMPLETED
NA
ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis
NCT02486068
UNKNOWN
NA
ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation
NCT00300131
COMPLETED
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
NCT01583608
COMPLETED
ENdothelial Healing Assessment With Novel Coronary tEchnology
NCT02747199
COMPLETED
NA
Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction
NCT02890589
COMPLETED
NA
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
NCT01249027
COMPLETED
Bioresorbable Sirolimus-eluting scaffold in de Novo Coronary Artery Lesions
NCT07022587
RECRUITING
NA
Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis
NCT03529006
UNKNOWN
NA
The ABSORB Bioresorbable Scaffold Below the Knee (BTK) Study
NCT02793349
TERMINATED
NA
ABSORB PHYSIOLOGY Clinical Investigation
NCT01308346
TERMINATED
NA
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
NCT01178268
COMPLETED
PHASE4
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
NCT02305485
UNKNOWN
NA
Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
NCT02066623
COMPLETED
Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period
NCT00882219
COMPLETED
PHASE3
A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions
NCT02796157
UNKNOWN
NA
A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction
NCT01942070
UNKNOWN
NA
Study of ABSORB Stent in Acute Myocardial Infarction
NCT02071342
UNKNOWN
DISsection RE-entry Evaluation With Absorb Bioresorbable Vascular Scaffolds in CTO.
NCT02936011
UNKNOWN
NA
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
NCT01894152
COMPLETED
Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions
NCT02229864
COMPLETED
NA
XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)
NCT02513732
COMPLETED